Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 41.0% in the third quarter, HoldingsChannel reports. The firm owned 31,489 shares of the company’s stock after selling 21,919 shares during the quarter. Principal Financial Group Inc.’s holdings in Elanco Animal Health were worth $463,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of ELAN. Benjamin F. Edwards & Company Inc. lifted its stake in Elanco Animal Health by 337.7% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after acquiring an additional 1,361 shares during the period. ORG Wealth Partners LLC purchased a new position in shares of Elanco Animal Health during the third quarter worth $29,000. nVerses Capital LLC acquired a new position in Elanco Animal Health during the second quarter valued at $32,000. ORG Partners LLC purchased a new stake in Elanco Animal Health in the second quarter valued at $31,000. Finally, Quarry LP acquired a new stake in Elanco Animal Health during the 2nd quarter worth about $40,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 0.3 %

ELAN stock opened at $13.36 on Monday. The company has a market cap of $6.60 billion, a price-to-earnings ratio of 33.40, a price-to-earnings-growth ratio of 1.40 and a beta of 1.41. The company has a fifty day moving average price of $13.70 and a 200 day moving average price of $14.75. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a 12 month low of $11.40 and a 12 month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health’s quarterly revenue was down 3.6% on a year-over-year basis. During the same period last year, the firm posted $0.18 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently commented on ELAN shares. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $17.00 to $15.00 in a report on Thursday, September 19th. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a research note on Thursday, September 19th. Finally, Barclays lifted their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $17.14.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.